Quantum Surgical announced today that it received FDA 510(k) clearance for its Epione interventional oncology robotics platform.
Montpellier, France-based Quantum Surgical designed Epione, a robot-assisted system, to plan, target, deliver and confirm tumor ablation in minimally invasive liver cancer treatment.
According to a news release, Epione enables clinicians to perform safe and effective percutaneous tumor ablations, expanding the option of such treatment to more patients battling liver cancer. Clearance permits marketing for the Epione interventional oncology robot in the U.S., with Quantum Surgical planning to extend indications for the platform to other organs.
Quantum Surgical added that it also has intentions to develop artificial intelligence (AI)-based decision-support features for the Epione platform.
“This clearance enables interventional oncologists to access state-of-the-art technology that has the potential to improve clinical outcomes and patients’ lives,” Quantum Surgical President and Co-Founder Bertin Nahum said in the release. “We believe that the clinical adoption of innovative robotic solutions like Epione will be a significant step toward allowing more patients to benefit from minimally invasive therapies in cancer treatment.”